Tharimmune Corp (THAR) - Multiplikator Forward P/S
Tharimmune, Inc. (THAR) is mitigating regulatory risks by developing a diversified portfolio of drugs to combat cancer and skin pathologies. The forward price-to-sales ratio visualizes market expectations, where the level captures the current state. The company's ecosystem focuses on pruritus therapy and liver diseases. The business is currently at the start of clinical trials and relies exclusively on venture capital investments.
Ringkesan rincian data analitis Tharimmune Corporation (THAR)
- rega saiki lan proyeksi nilai saham:
- indikator kapitalisasi pasar:
- statistik nilai buku emiten:
- indikator beban kredit lan likuiditas emiten:
Utang marang Ekuitas Tharimmune, Inc.|THAR - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Tharimmune, Inc.|THAR - Gunggung utang perusahaan|Utang marang nilai buku Tharimmune Corporation|THAR - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Tharimmune|Rasio cepet tharimmune.com
- data bathi bisnis lan rasio investasi:
THAR - Penghasilan resik perusahaan|Bathi mangsa ngarep Tharimmune, Inc.|THAR - Nilai perusahaan marang bathi resik|Pangali Forward P/E Tharimmune Corp|THAR - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Tharimmune Corporation|THAR - Bathi operasional sadurunge amortisasi|Bathi resik saben saham (EPS TTM) Tharimmune|THAR - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan tharimmune.com|THAR - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Tharimmune, Inc.
- statistik dodolan lan pendapatan perusahaan:
Analisis kabeh metrik perusahaan:Tharimmune (THAR)
The selection of promising issuers is based on comparing market value with expected cash flows using multiples. The forward P/S ratio reflects the relationship between current capitalization and projected revenue; however, for Tharimmune, Inc. (THAR), this calculation is complicated by geopolitical barriers hindering clinical trials and drug certification, making the forward P/S ratio trend a critical indicator of market optimism.
Pesaing Tharimmune, Inc.
Multiplikator Forward P/S ONC (BeiGene)|Rega forward marang dodolan HALO|RevMed - Multiplikator Forward P/S|AAPG - Multiplikator Forward P/S|CG Oncology, Inc. (CGON) - Rasio rega marang prakiraan pendapatan|urogen.com - Rega forward marang dodolan|BCAX (Bicara Therapeutics) - Multiplikator Forward P/S|Personalis Inc (PSNL) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Erasca Corp (ERAS)|Multiplikator forward rega marang pendapatan Delcath Corp DCTH|Rasio rega marang prakiraan pendapatan Y-mAbs Therapeutics YMAB|AURA - Multiplikator forward rega marang pendapatan|CADL: Multiplikator forward rega marang pendapatan|ARAY - Multiplikator Forward P/S|sellaslifesciences.com (SLS) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan ACTU|CTOR (Citius Oncology, Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep TuHURA HURA|Multiplikator forward rega marang pendapatan TARA (Protara Therapeutics, Inc.)|FATE (Fate Therapeutics Inc) - Rega forward marang dodolan|Multiplikator Forward P/S WHWK (Aadi Bioscience)|Rasio kapitalisasi marang dodolan sing dikarepake TScan Therapeutics Inc (TCRX)|CSBR - Rasio rega marang prakiraan pendapatan|XBIT (XBiotech Inc.) - Kapitalisasi marang prakiraan pendapatan|CVM: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan OS Therapies Inc.|Multiplikator forward rega marang pendapatan RADX|Artiva (ARTV) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan ANL (Adlai Nortye Ltd.)|Rasio rega marang pendapatan sing dikarepake VERU|Multiplikator Forward P/S TPST (Tempest Therapeutics, Inc.)|Rega forward marang dodolan XLO|Enochian BioSciences - Multiplikator Forward P/S|MURA - Multiplikator Forward P/S|kairospharma.com (KAPA) - Rasio rega marang prakiraan pendapatan|OnKure Therapeutics - Rega forward marang dodolan|GDTC (CytoMed Therapeutics Ltd) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Curis Corp (CRIS)|Multiplikator Forward P/S APLM|Multiplikator Forward P/S advanbiomed.com (ADVB)|Rasio rega marang prakiraan pendapatan Genprex, Inc. GNPX|CLDI: Kapitalisasi marang prakiraan pendapatan|Sunshine Biopharma, Inc. - Multiplikator Forward P/S|Xenetic Biosciences (XBIO) - Multiplikator forward rega marang pendapatan|SLRX: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Kitov Pharma (PPBT)|Rasio rega marang prakiraan pendapatan American Oncology Network Inc|BGNE: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan CKPT (Checkpoint Therapeutics, Inc.)|ELEV (elevationoncology.com) - Rega forward marang dodolan|Multiplikator Forward P/S ICAD (iCAD)|IKNA - Multiplikator forward rega marang pendapatan|NTBL: Multiplikator forward rega marang pendapatan|VIRX - Multiplikator Forward P/S|MorphoSys (MOR) - Rasio rega marang prakiraan pendapatan|NAYA Biosciences Inc - Rega forward marang dodolan|AAPGV (Ascentage Pharma Group Ltd) - Multiplikator Forward P/S
